

Individual Laboratory Report - Lab 3538

LUNG CANCER (NSCLC) [Tissue] : Lung Common Biomarkers EQA Scheme PLUS 1 x Set of additional samples : Lung New and Emerging Biomarkers EQA Scheme PLUS 2 x Set of Additional Samples | 2025

SUMMARY OF YOUR PERFORMANCE IN THIS EQA

Assessment Category	Performance (mean score) ¹
Genotyping	2.00
Interpretation	2.00
Patient Identifiers & Clerical Accuracy	2.00
EQA Result (PASS or POOR)	PASS

CASE SPECIFIC FEEDBACK

Case 1

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0) Comment only (0) The statement 'Following indicative markers included in lung cancer guidelines should be tested further' may be misleading. In the case of a detected KRAS mutation, it is rather unlikely that additional driver mutations in other genes will be present.
Interpretation	2.00	All essential interpretative elements provided (0) Please avoid the use of specific drug names and refer to the drug class instead (0)
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)

Case 2

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Key: Green (Pass), Red (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

3538

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org Web: <https://www.emqn.org/>



4367

Case 3

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Case 4

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Case 5

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Case 6

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0) Minor HGVS error e.g. missing brackets around the protein or p. inside brackets (0)
Interpretation	2.00	Please avoid the use of specific drug names and refer to the drug class instead (0) Comment only (0) The statement 'Following indicative markers included in lung cancer guidelines should be tested further' may be misleading. In the case of a detected EGFR mutation, it is rather unlikely that additional driver mutations in other genes will be present.
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)

Case 7

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Case 8

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Case 9

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Case 10

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)

Key: 1 Green (Pass), 2 Red (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

3538

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org Web: <https://www.emqn.org/>



This Individual Laboratory Report should be read in conjunction with scheme summary report.

Thank you for participating in this year's EQA, we look forward to you participating again next year.

Report approved and authorised by Simon Patton (22 January 2026) on behalf of EMQN.



Dr. Simon Patton (CEO)

Key: ¹ **Green** (Pass), **Red** (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org **Web:** <https://www.emqn.org/>

3538



4367